Blueprint Medicines Corp Up 14.76% To $58.07 After Earnings Miss

Blueprint Medicines Corp (BPMC) said before open Tuesday that it lost $2.68 per share in quarter two 2022.

On the revenue line, the company reported $36.5 million, missing estimates by $693 thousand.

In the same quarter a year ago, the company lost $1.86 per share on revenue of $27.3 million.

The stock is up 14.76% to $58.07 after the report.

Blueprint Medicines Corp's earnings expanded faster than revenues, signaling widening profit margins.

Wall Street Analysts had an average rating of Buy on the stock prior to the report.

Trading in the five days leading up to the report earned Blueprint Medicines Corp a Bearish Sentiment Rank from InvestorsObserver.

Blueprint Medicines Corp has performed poorly during the past few months, garnering a low Long-Term Technical Rank by InvestorsObserver of 6, putting Blueprint Medicines Corp in the bottom 25% of stocks. The firm was recently trading at a 52-week low of $43.46 on June 14, 2022 and set a 52-week high on November 10, 2021 at $117.86.

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.